ChariotMS is a groundbreaking multi-sited phase 2 clinical trial that will test whether Cladribine (MAVENCLAD®), a drug already licensed for highly active relapsing MS, can help people with advanced MS (pwAMS), maintain the use of their upper limbs (arms and hands). The Anne Rowling Clinic is one of twenty sites recruiting up to 200 participants who score between 6.5 and 8.5 on the Expanded Disability Status Scale (EDSS). This means that some people who have never been eligible for a trial before will be able to take part (other trial participation criteria will apply). Uniquely instead of the usual walking ability test to determine whether the drug is effective, the ChariotMS study will use an arm-hand coordination test called the 'Nine-Hole Peg Test.' This test measures how hand and arm function changes over time.
The trial is led by Professor Klaus Schmierer, Queen Mary University of London & Barts NHS Health Trust. The lead principal investigator for ChariotMS at the Anne Rowling Clinic is Dr Don Mahad.
Further information
Find out more about the ChariotMS study (external website)
